Cases & Deals

  • Home
  • Practices
  • Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®

Share

Genzyme (Sanofi) develops patent portfolio for antisense drug Kynamro®

January 2016

Clients Genzyme Corporation

Jones Day represented Genzyme Corporation (Sanofi) in developing patent portfolios related to the apolipoprotein B-targeting antisense drug, Kynamro® (mipomersen), which was the first antisense drug to reach the market and used for the treatment of homozygous familial hypercholesterolemia.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.